Edgewise Therapeutics (NASDAQ:EWTX) Issues Earnings Results

27 Feb 2026, 13:22 by Amy Steele · The Cerbat Gem

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) issued its earnings results on Thursday. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04), FiscalAI reports.

Edgewise Therapeutics Stock Down 0.1%

EWTX stock traded down $0.04 during mid-day trading on Friday, reaching $29.63. 310,314 shares of the stock traded hands, compared to its average volume of 985,393. The firm has a market capitalization of $3.14 billion, a PE ratio of -18.73 and a beta of 0.27. The business has a 50-day moving average of $27.53 and a two-hundred day moving average of $21.05. Edgewise Therapeutics has a 52 week low of $10.60 and a 52 week high of $31.82.

Analyst Ratings Changes

Several research analysts have weighed in on EWTX shares. JPMorgan Chase & Co. upped their target price on Edgewise Therapeutics from $33.00 to $34.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Evercore reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Edgewise Therapeutics in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Edgewise Therapeutics in a research note on Wednesday, January 21st. Wedbush dropped their price target on shares of Edgewise Therapeutics from $35.00 to $32.00 and set an “outperform” rating on the stock in a research note on Friday, November 7th. Finally, Wall Street Zen upgraded shares of Edgewise Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, February 15th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Edgewise Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $36.36.

Get Our Latest Report on Edgewise Therapeutics

Insider Buying and Selling at Edgewise Therapeutics

In related news, Director Badreddin Edris sold 115,471 shares of the business’s stock in a transaction dated Wednesday, January 21st. The stock was sold at an average price of $29.44, for a total transaction of $3,399,466.24. Following the completion of the transaction, the director owned 19,820 shares of the company’s stock, valued at approximately $583,500.80. The trade was a 85.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 23.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC grew its stake in shares of Edgewise Therapeutics by 23.9% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock worth $71,000 after acquiring an additional 550 shares during the last quarter. California State Teachers Retirement System grew its position in Edgewise Therapeutics by 2.4% in the 2nd quarter. California State Teachers Retirement System now owns 36,878 shares of the company’s stock worth $483,000 after purchasing an additional 850 shares during the last quarter. Creative Planning grew its position in Edgewise Therapeutics by 6.7% in the 3rd quarter. Creative Planning now owns 18,036 shares of the company’s stock worth $293,000 after purchasing an additional 1,126 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Edgewise Therapeutics by 14.9% during the second quarter. Tower Research Capital LLC TRC now owns 9,148 shares of the company’s stock valued at $120,000 after buying an additional 1,188 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Edgewise Therapeutics by 3.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 36,759 shares of the company’s stock valued at $912,000 after buying an additional 1,221 shares during the period.

Edgewise Therapeutics Company Profile

(Get Free Report)

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.